Acute Myeloid Leukemia Archives

GammaDelta Therapeutics initiates first-in-human phase 1 trial of GDX012 for the treatment of acute myeloid leukemia

GammaDelta Therapeutics Ltd. (GDT), a biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for

Refractory acute myeloid leukemia (AML) is a very challenging complication in the management of AML. In this condition, the disease

Essential thrombocythemia (ET) is a rare condition affecting the bone marrow, resulting in an overproduction of platelets. It usually affects